DOCSLIB.ORG

Charge Description Price

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Charge Description Price Charge Description Price 1.5MM LOCK PLATE STRAIGHT $1632 1.5MM LOCK PLATE T-SHAPE $1632 1.5MM LOCK PLATE T-SHAPE SMALL $1952 1.5MM LOCK PLATE TY-SHAPE $1632 1.5MM LOCK PLATE WEB $1800 1.5MM LOCK PLATE Y-SHAPE $1632 2 HOLE STRAIGHT PLATE $1384 2 HOLE STRAIGHT PLATE W/ COMP $1384 2.4/2.7MM VA-LCP T-FUSION PL 3 $2824.89 2.4/2.7MM VA-LCP TMT FUSION PL $2601.69 2.4MM LCP WRIST PLATE 170MM $5178.6 2.5MM LOCK PLATE STRAIGHT $1704 2.5MM LOCK PLATE T-SHAPE $1704 2.5MM LOCK PLATE TY-SHAPE $1704 2.5MM LOCK PLATE WEB $1896 2.5MM LOCK PLATE Y-SHAPE $1704 2.7MM VA-LCKING CALCANEAL PL L $3050.88 2.7MM VA-LCKING CALCANEAL PL L $3512.28 2.7MM VA-LCKING CALCANEAL PL S $2937.87 2.7MM VA-LCKING CALCANEAL PL S $3382.2 212NM ATTUNE FB CAP $6105 25GA WHIT 17GA WEISS $114.96 28 PLATE 15MM 2-HOLECOMP 1.5MM $2812.5 28 PLATE 15MM 2-HOLELOCK 1.1MM $2812.5 28 PLATE 15MM 2-HOLELOCK 1.5MM $2812.5 28 PLATE 20MM 2-HOLECOMP 1.1MM $2812.5 28 PLATE 20MM 2-HOLECOMP 1.5MM $2812.5 28 PLATE 20MM 2-HOLELOCK 1.1MM $2812.5 28 PLATE 20MM 2-HOLELOCK 1.5MM $2812.5 28 PLATE 25MM 2-HOLECOMP 1.5MM $2812.5 28 PLATE 25MM 2-HOLELOCK 1.1MM $2812.5 28 PLATE 25MM 2-HOLELOCK 1.5MM $2812.5 28 PLATE 25MM 3-HOLECOMP 1.1MM $2812.5 28 PLATE 25MM 3-HOLECOMP 1.5MM $2812.5 28 PLATE 30MM 3-HOLECOMP 1.1MM $2812.5 28 PLATE 30MM 3-HOLECOMP 1.5MM $2812.5 28 PLATE 35MM 3-HOLECOMP 1.5MM $2812.5 28 PLATETM 4HOLE STCOMP 1.5MM $2962.5 28 PLATETM 4-HOLE STLOCK 1.5MM $2962.5 28 PLATETM 5-HOLE STCOMP 1.5MM $2962.5 3DICROSSCHECK LAG 3.5X18 $748 3DICROSSCHECK LAG 3.5X20 $748 3DICROSSCHECK LAG 3.5X22 $748 3DICROSSCHECK LAG 3.5X24 $748 3DICROSSCHECK LAG 3.5X26 $748 3DICROSSCHECK LAG 3.5X28 $748 3DICROSSCHECK LAG 3.5X30 $748 3DICROSSCHECK LAG 3.5X32 $748 3DICROSSCHECK LAG 3.5X34 $748 3DICROSSCHECK LAG 3.5X36 $748 3DICROSSCHECK LAG 3.5X38 $748 3DICROSSCHECK LAG 3.5X40 $748 3DICROSSCHECK LAP 0 LEFT $3876 3DICROSSCHECK LAP 0 RIGHT $3876 3DICROSSCHECK LAP 2 LEFT $3876 3DICROSSCHECK LAP 2 RIGHT $3876 3DICROSSCHECK MTP LEFT $3876 3DICROSSCHECK MTP RIGHT $3876 3DICROSSCHECK UTIL PLT 5 HOLE $3201.6 3DICROSSCHECK Y PLATE $3056.4 3DMAX LIGHT MESH, LEFT, LARGE $791.6 4 HOLE STRAIGHT PINCH PLATE $3114 4 HOLE STRAIGHT PLATE $1844 5TH MET HOOK PLATE $3114 5TH MET Y-PLATE LEFT $3114 5TH MET Y-PLATE RIGHT $3114 6 HOLE STRAIGHT PINCH PLATE $3462 6 HOLE STRAIGHT PLATE $1844 6 HOLE T-PLATE $1557 6IN AML SM STATURE 12.0MM $3542.4 7 HOLE T-PLATE $1731 8 HOLE STRAIGHT PLATE $2076 8 HOLE T-PLATE $1902 ABACAVIR 300 MG TABLET $36.43 ABLATE L/R FIBRIL W/ISOLATED PULM VEIN $13682 ABSORB HEMO PARTICLE ARISTA 1G $323.52 ABSORB HEMO PARTICLE ARISTA 3G $643.8 ACAMPROSATE 333 MG TABLET,DELAYED RELEASE $23.95 ACAMPROSATE 333 MG TABLET,DELAYED RELEASE $24.62 ACAMPROSATE 333 MG TABLET,DELAYED RELEASE $24.64 ACARBOSE 50 MG TABLET $21.68 ACE FIX BALL JOINT UNIVERSAL $840 ACE FIX COUPLING ARTICULATION $1530 ACE FIX ROD CONNECTING ADJ $520 ACEBUTOLOL 200 MG CAPSULE $20.38 ACEBUTOLOL 200 MG CAPSULE $20.89 ACETABULAR LCKNG RNG 27 105427 $800 ACETAMINOPHEN 1,000 MG/100 ML (10 MG/ML) INTRAVENOUS SOLUTION $111.50 ACETAMINOPHEN 120 MG RECTAL SUPPOSITORY $20.61 ACETAMINOPHEN 120 MG RECTAL SUPPOSITORY $20.69 ACETAMINOPHEN 120 MG RECTAL SUPPOSITORY $21.39 ACETAMINOPHEN 325 MG RECTAL SUPPOSITORY $21.32 ACETAMINOPHEN 325 MG RECTAL SUPPOSITORY $21.33 ACETAMINOPHEN 325 MG TABLET $20.03 ACETAMINOPHEN 325 MG TABLET $20.04 ACETAMINOPHEN 325 MG TABLET $20.06 ACETAMINOPHEN 325 MG TABLET $20.07 ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION $20.09 ACETAMINOPHEN 325 MG/10.15 ML ORAL SUSPENSION $21.27 ACETAMINOPHEN 500 MG TABLET $20.08 ACETAMINOPHEN 650 MG RECTAL SUPPOSITORY $21.58 ACETAMINOPHEN 650 MG RECTAL SUPPOSITORY $21.61 ACETAMINOPHEN 80 MG CHEWABLE TABLET $20.13 ACETAMINOPHEN ER 650 MG TABLET,EXTENDED RELEASE $20.18 ACETAZOLAMIDE 125 MG TABLET $29.94 ACETAZOLAMIDE 250 MG TABLET $26.57 ACETAZOLAMIDE 500 MG SOLUTION FOR INJECTION $58.09 ACETAZOLAMIDE ER 500 MG CAPSULE,EXTENDED RELEASE $28.72 ACETAZOLAMIDE ER 500 MG CAPSULE,EXTENDED RELEASE $29.32 ACETAZOLAMIDE ER 500 MG CAPSULE,EXTENDED RELEASE $46.11 ACETIC ACID (BULK) 3 % LIQUID $31.12 ACETIC ACID (BULK) LIQUID $31.12 ACETIC ACID (BULK) LIQUID $31.48 ACETIC ACID 0.25 % IRRIGATION SOLUTION $52.50 ACETYLCYSTEINE 200 MG/ML (20 %) INTRAVENOUS SOLUTION $198.55 ACETYLCYSTEINE 200 MG/ML (20 %) INTRAVENOUS SOLUTION $481.60 ACETYLCYSTEINE 200 MG/ML (20 %) INTRAVENOUS SOLUTION $526.75 ACETYLCYSTEINE 200 MG/ML (20 %) SOLUTION $40.78 ACETYLCYSTEINE 200 MG/ML (20 %) SOLUTION $42.85 ACIS PROTI LOR/M 8MM $3225 ACIS PROTI LOR/M 9MM $3225 ACTIVATED CHARCOAL 25 GRAM ORAL SUSPENSION $57.80 ACTIVATED CHARCOAL 25 GRAM/120 ML ORAL SUSPENSION $55.64 ACTIVATED CHARCOAL 25 GRAM/120 ML ORAL SUSPENSION $95.96 ACTIVATED CHARCOAL 50 GRAM/240 ML ORAL SUSPENSION $96.32 ACUSNARE NDL TIP STD OVAL $102 ACYCLOVIR 200 MG CAPSULE $20.00 ACYCLOVIR 200 MG CAPSULE $20.01 ACYCLOVIR 200 MG CAPSULE $20.37 ACYCLOVIR 200 MG CAPSULE $28.08 ACYCLOVIR 200 MG/5 ML ORAL SUSPENSION $30.73 ACYCLOVIR 200 MG/5 ML ORAL SUSPENSION $35.62 ACYCLOVIR 400 MG TABLET $20.66 ACYCLOVIR 5 % TOPICAL OINTMENT $132.19 ACYCLOVIR 5 % TOPICAL OINTMENT $354.75 ACYCLOVIR 5 % TOPICAL OINTMENT $4,148.89 ACYCLOVIR 5 % TOPICAL OINTMENT $447.82 ACYCLOVIR 800 MG TABLET $20.86 ACYCLOVIR 800 MG TABLET $20.95 ACYCLOVIR SODIUM 50 MG/ML INTRAVENOUS SOLUTION $122.20 ACYCLOVIR SODIUM 50 MG/ML INTRAVENOUS SOLUTION $47.45 ACYCLOVIR SODIUM 50 MG/ML INTRAVENOUS SOLUTION $55.50 ACYCLOVIR SODIUM 50 MG/ML INTRAVENOUS SOLUTION $84.15 ADAPT VERSA DIAL 25MM $600 ADENOSINE (DIAGNOSTIC) 3 MG/ML INTRAVENOUS SOLUTION $206.88 ADENOSINE (DIAGNOSTIC) 3 MG/ML INTRAVENOUS SOLUTION $501.03 ADENOSINE 3 MG/ML INTRAVENOUS SOLUTION $42.97 ADENOSINE 3 MG/ML INTRAVENOUS SOLUTION $43.08 ADENOSINE 3 MG/ML IV $45.93 ADPR STG1 SLCT NK SPCR MLD +6 $1840 ADVANIX BILIARY STENT 10X12 $530.64 ADVANIX BILIARY STENT 10X15 $530.64 ADVANIX BILIARY STENT 10X5 $530.64 ADVANIX BILIARY STENT 10X7 $530.64 ADVANIX BILIARY STENT 10X9 $530.64 ADVANIX BILIARY STENT 7X12 $530.64 ADVANIX BILIARY STENT 7X15 $530.64 ADVANIX BILIARY STENT 7X5 $530.64 ADVANIX BILIARY STENT 7X7 $530.64 ADVANIX BILIARY STENT 7X9 $530.64 AKIN PLATE STRAIGHT, 10MM $1875 AKIN PLATE MEDIALANATOMIC 10MM $1875 AKIN PLATE W/COMPRESSION, 10MM $1875 ALBENDAZOLE 200 MG TABLET $704.05 ALBUMIN, HUMAN 25 % INTRAVENOUS SOLUTION $115.75 ALBUMIN, HUMAN 25 % INTRAVENOUS SOLUTION $77.88 ALBUMIN, HUMAN 25 % INTRAVENOUS SOLUTION $93.13 ALBUMIN, HUMAN 25 % INTRAVENOUS SOLUTION $98.00 ALBUMIN, HUMAN 5 % INTRAVENOUS SOLUTION $115.63 ALBUMIN, HUMAN 5 % INTRAVENOUS SOLUTION $130.63 ALBUMIN, HUMAN 5 % INTRAVENOUS SOLUTION $140.00 ALBUMIN, HUMAN 5 % IV $130.63 ALBUTEROL SULFATE 1.25 MG/3 ML SOLUTION FOR NEBULIZATION $40.82 ALBUTEROL SULFATE 1.25 MG/3 ML SOLUTION FOR NEBULIZATION $41.39 ALBUTEROL SULFATE 2.5 MG/3 ML (0.083 %) NEB SOLUTION $40.38 ALBUTEROL SULFATE 2.5 MG/3 ML (0.083 %) SOLUTION FOR NEBULIZATION $40.41 ALBUTEROL SULFATE CONCENTRATE 2.5 MG/0.5 ML SOLUTION FOR NEBULIZATION $40.87 ALBUTEROL SULFATE CONCENTRATE 5 MG/ML(0.5 %) SOLUTION FOR NEBULIZATION $76.35 ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER $158.57 ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER $179.49 ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER $202.53 ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER $27.92 ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER $31.17 ALBUTEROL SULFATE HFA 90 MCG/ACTUATION AEROSOL INHALER $84.06 ALENDRONATE 35 MG TABLET $21.32 ALENDRONATE 5 MG TABLET $20.66 ALENDRONATE 5 MG TABLET $20.94 ALENDRONATE 70 MG TABLET $22.82 ALENDRONATE 70 MG TABLET $25.26 ALEXIS XSMALL WOUND PROTECTOR $112 ALFUZOSIN ER 10 MG TABLET,EXTENDED RELEASE 24 HR $20.26 ALFUZOSIN ER 10 MG TABLET,EXTENDED RELEASE 24 HR $20.99 ALISKIREN 300 MG TABLET $39.59 ALLOGRAFT MTF TRINITY ELITE LG $7592.0625 ALLOGRAFT MTF TRINITY ELITE ME $4650.75 ALLOGRAFT MTF TRINITY ELITE SM $1800 ALLOPURINOL 100 MG TAB $21.02 ALLOPURINOL 100 MG TABLET $20.51 ALLOPURINOL 100 MG TABLET $20.73 ALLOPURINOL 100 MG TABLET $20.89 ALLOPURINOL 300 MG TABLET $21.51 ALLOPURINOL 300 MG TABLET $21.79 ALPHA-1-PROTEINASE INHIBITOR (HUMAN) 1,000 MG INTRAVENOUS SOLUTION $1,309.00 ALPRAZOLAM 0.25 MG TABLET $20.07 ALPRAZOLAM 0.25 MG TABLET $20.12 ALPRAZOLAM 0.5 MG TABLET $20.02 ALPRAZOLAM 0.5 MG TABLET $20.16 ALPRAZOLAM 0.5 MG TABLET $20.34 ALPRAZOLAM 1 MG TABLET $20.01 ALPRAZOLAM 1 MG TABLET $20.07 ALPROSTADIL 500 MCG/ML INJECTION SOLUTION $307.22 ALTEPLASE 100 MG INTRAVENOUS SOLUTION $20,712.05 ALTEPLASE 100 MG IV SOLUTION $10,376.03 ALTEPLASE 100 MG IV SOLUTION $20,712.05 ALTEPLASE 2 MG INTRA-CATHETER SOLUTION $399.55 ALTEPLASE 2 MG INTRA-CATHETER SOLUTION $441.91 ALTEPLASE 2 MG SOLUTION FOR INJECTION $399.55 ALTEPLASE 2 MG SOLUTION FOR INJECTION $441.91 ALTEPLASE 50 MG INTRAVENOUS SOLUTION $10,376.03 ALTEPLASE 50 MG IV SOLUTION $10,376.03 ALTEPLASE 50 MG IV SOLUTION $17,611.24 ALTEPLASE 50 MG IV SOLUTION $2,067,245.00 ALTEPLASE 50 MG IV SOLUTION $20,712.05 ALTEPLASE 50 MG IV SOLUTION $3,140.81 ALTIS SLING $3302.4 ALUMINUM-MAG HYDROXIDE-SIMETHICONE 200 MG-200 MG-20 MG/5 ML ORAL SUSP $20.06 ALUMINUM-MAG HYDROXIDE-SIMETHICONE 200 MG-200 MG-20 MG/5 ML ORAL SUSP $20.93 ALVIMOPAN 12 MG CAPSULE $515.27 AMANTADINE HCL 100 MG CAPSULE $23.77 AMANTADINE HCL 100 MG CAPSULE $26.36 AMANTADINE HCL 50 MG/5 ML ORAL SOLUTION $25.20 AMANTADINE HCL 50 MG/5 ML ORAL SOLUTION $28.60 AMIKACIN 1,000 MG/4 ML INJECTION SOLUTION $63.32 AMILORIDE 5 MG TAB $22.57 AMILORIDE 5 MG TABLET $21.02 AMILORIDE 5 MG-HYDROCHLOROTHIAZIDE 50 MG TABLET $21.03 AMINO ACID 4.25 % IN 10 % DEXTROSE INTRAVENOUS SOLUTION $85.00 AMINO ACID 5 % IN 15 % DEXTROSE INTRAVENOUS
Load more

Recommended publications
  • NOTE: the Following Are Shirley Ryan Abilitylab's Standard Charges As of Jan. 1, 2019. These Standard Charges Often Do Not
    NOTE: The following are Shirley Ryan AbilityLab's standard charges as of Jan. 1, 2019. These standard charges often do not reflect what a patient or their insurance company/payer may be required to pay. Contact Patient Financial Services at 312-238-6039 for more information. Description Price 11-Deoxycortisol, Urine Random $531 12 Lead Ekg, Tracing Only $245 17 Hydroxycorticosteroids, Urine Timed $363 17 Hydroxyprogesterone, Serum $172 17 Ketosteroids, Urine Timed $273 17-Ketosteroids with Creatinine, Urine Random $273 2D Gait Analysis Charge(95999) $2,174 5' Nucleotidase, Serum $269 5.5 PDC PEDS CUFFED TRACH $226 5-HIAA-24 Hr Urine $99 A4566 Shoulder sling or vest design, abduction res $226 A4595 FES Electrode, each $38 A6545 Gradient Compression Wrap, Non-Elastic, Belo $171 ABO Rh Type $106 Above Knee Nylon Hose PR $83 Above Knee Suction Sheath $131 Above knee, for proximal femoral focal deficiency, $14,344 Above knee, molded socket, open end, SACH foot, en $10,751 Above knee, molded socket, single axis constant fr $10,935 Above knee, short prosthesis, no knee joint (""stu_L5210 $8,682 Above knee, short prosthesis, no knee joint (""stu_L5220 $7,429 ACAPELLA DH GREEN VIBRATORY PEP W/MOUTHPIECE DEVIC $181 Acetabuloplasty (27120) $4,493 Acetone, Serum $27 Acetylcholine Receptor Binding Antibody $405 Acid Phosphatase $66 Acid Phosphatase, Prostatic fraction $66 ACNE SURGERY MILIA CYSTS (10040) $530 Acorn Nebulizer $174 Activated PTT/Partial Thromboplastin Time $109 Active Wound Care > 20 cm Units $171 Active Wound Care/20 cm or < Units $171 Acupuncture with E-Stim. Each additional 15 minute $65 Acupuncture with E-Stim.
    [Show full text]
  • Dexamethasone Sodium Phosphate Injection, USP)
    HEXADROL® PHOSPHATE INJECTION (dexamethasone sodium phosphate injection, USP) DESCRIPTION — Hexadrol® Phosphate Injection (dexamethasone sodium phosphate injection, USP) is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly. Dexamethasone Sodium Phosphate, C22H28FNa2O8P, has a molecular weight of 516.41 and chemically is Pregn-4-ene-3, 20-dione, 9-fluoro-11, 17-dihydroxy-16-methyl-21 (phosphonooxy)-, disodium salt, (11β, 16α). It occurs as a white to creamy white powder, is exceedingly hygroscopic, is soluble in water and its solutions have a pH between 7.5 and 10.5. It has the following structural formula: Hexadrol® Phosphate Injection is available in 4 mg/mL and 10 mg/mL concentrations. Each mL of Hexadrol® Phosphate Injection 4 mg/mL, contains dexamethasone sodium phosphate, USP equivalent to 4 mg dexamethasone phosphate; 1 mg sodium sulfite; 10 mg benzyl alcohol (preservative). Made isotonic with sodium citrate. pH adjusted with citric acid or sodium hydroxide. 1 Reference ID: 3593917 Each mL of Hexadrol® Phosphate Injection 10 mg/mL, contains dexamethasone sodium phosphate, USP equivalent to 10 mg dexamethasone phosphate; 1.5 mg sodium sulfite; 10 mg benzyl alcohol (preservative). Made isotonic with sodium citrate. pH adjusted with citric acid or sodium hydroxide. ACTIONS — Naturally occurring glucocorticoids (hydrocortisone), which also have salt- retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • Vertebroplasty (Repair of Vertebrae with Bone Cement)
    Patient information – Radiology Unit Tel 0118 322 7991 Vertebroplasty (repair of vertebrae with bone cement) Introduction This leaflet tells you about the procedure known as “vertebroplasty”, explains what is involved, the benefits and possible risks. It is not meant to replace informed discussion between you and your doctor but can act as a starting point for such a discussion. You should have plenty of time to discuss this procedure with the doctor who will be performing the procedure. What is vertebroplasty? Vertebroplasty is a procedure used to strengthen a collapsed spinal vertebra that has fractured and usually lost height due to osteoporosis or, less commonly, tumour infiltration or trauma. Vertebroplasty is primarily aimed at relieving the patient’s pain, to allow a rapid return to the previous level of activity, and secondarily to prevent further vertebral collapse. It is minimally invasive which means that patients suffer less disruption, face less risk and recover more quickly than with conventional open surgery. It is most effective when the fracture is relatively recent and particularly in patients who are very debilitated by the pain of the fracture or who cannot tolerate adequate quantities of painkilling medication. In some circumstances, vertebroplasty can be very effective even if the fracture is many months or even years old. Vertebroplasty is accomplished by injecting orthopaedic cement through a needle into the fractured bone; essentially forming an internal cast to stabilise the fracture similar to the principle of using plaster cast on an arm fracture. Typically, vertebroplasty is recommended if simpler treatments, such as bed rest, back bracing or pain medication have been ineffective, or if the side effects of analgesia have become problematic, such as causing stomach ulcers or drowsiness.
    [Show full text]
  • Download Book
    Methods in Molecular Biology 2000 Volkmar Weissig Tamer Elbayoumi Editors Pharmaceutical Nanotechnology Basic Protocols M ETHODS IN M OLECULAR B IOLOGY Series Editor John M. Walker School of Life and Medical Sciences University of Hertfordshire Hatfield, Hertfordshire AL10 9AB, UK For further volumes: http://www.springer.com/series/7651 Pharmaceutical Nanotechnology Basic Protocols Edited by Volkmar Weissig and Tamer Elbayoumi Department of Pharmaceutical Sciences, College of Pharmacy, Midwestern University, Glendale, AZ, USA Nanomedicine Center of Excellence in Translational Cancer Research, Midwestern University, Glendale, AZ, USA Editors Volkmar Weissig Tamer Elbayoumi Department of Pharmaceutical Sciences Department of Pharmaceutical Sciences College of Pharmacy, Midwestern University College of Pharmacy, Midwestern University Glendale, AZ, USA Glendale, AZ, USA Nanomedicine Center of Excellence Nanomedicine Center of Excellence in Translational Cancer Research in Translational Cancer Research Midwestern University Midwestern University Glendale, AZ, USA Glendale, AZ, USA ISSN 1064-3745 ISSN 1940-6029 (electronic) Methods in Molecular Biology ISBN 978-1-4939-9515-8 ISBN 978-1-4939-9516-5 (eBook) https://doi.org/10.1007/978-1-4939-9516-5 © Springer Science+Business Media, LLC, part of Springer Nature 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc.
    [Show full text]
  • Oxford® Policy Update Bulletin: December 2015 Oxford
    Oxford December 2015 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary.
    [Show full text]
  • Prescription Drugs Requiring Prior Authorization
    PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Revised 10/16 As part of our drug utilization management program, members must request and receive prior authorization for certain prescription drugs in order to use their prescription drug benefits. Below is a list of drugs that currently require prior authorization. This list will be updated periodically as new drugs that require prior authorization are introduced. As benefits may vary by group and individual plans, the inclusion of a medication on this list does not imply prescription drug coverage. The Schedule of Benefits contains a list of drug categories that require prior authorization. Prior authorization requests are processed by our pharmacy benefit manager, Express Scripts, Inc. (ESI). Physicians must call ESI to obtain an authorization. (1-800-842-2015). Drug Name Generic Name Drug Classification Abstral fentanyl citrate oral tablet Controlled Dangerous Substance Accu-Chek Test Strips blood glucose test strips Blood Glucose Test Strips Actemra tocilizumab Monoclonal Antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate OTFC Controlled Dangerous Substance Adcirca tadalafil Pulmonary Vasodilator Adempas riociguat Pulmonary Vasodilator Adlyxin lixisenatide Type 2 Diabetes Advocate Test Strips blood glucose test strips Blood Glucose Test Strips Aerospan** flunisolide Corticosteroids (Inhaled) Afrezza insulin Insulin (inhaled) Ampyra dalfampridine Multiple Sclerosis Agent Altoprev** lovastatin Cholesterol Alvesco** ciclesonide Corticosteroids
    [Show full text]
  • SUMMARY of PRODUCT CHARACTERISTICS 2.1 General Description 2.2 Qualitative and Quantitative Composition
    THERADOL 50 mg Effervescent tablets 1 Summary of product characteristics SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT THERADOL 50 mg Effervescent tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 2.1 General description Round, biplane white or off-white tablets with bevel-edges on both sides. 2.2 Qualitative and quantitative composition Tramadol hydrochloride 50 mg per effervescent tablet. This product also contains sodium 214 mg, lactose 75 mg and aspartame 10 mg per tablet. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Effervescent tablet. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Treatment of moderate to severe acute and chronic pain, such as pain due to surgery, trauma, malignancy. 4.2. Posology and method of administration Posology As with all analgesic drugs, the dose of THERADOL 50 mg Effervescent tablets should be adjusted according to the intensity of the pain and the sensitivity of the individual patient. The lowest effective dose for analgesia should generally be selected. Adults and children aged 12 years and over: The usual dose is 50 to 100 mg (1 to 2 effervescent tablets), 3 to 4 times a day. In children from 12 to 14 years, it is recommended to use the lowest dose. Geriatric patients THERADOL 50 mg Effervescent tablets 2 Summary of product characteristics A dose adjustment is not usually necessary in patients up to 75 years without clinically manifest hepatic or renal insufficiency. In elderly patients over 75 years elimination may be prolonged. Therefore, if necessary the dosage interval is to be extended according to the patient's requirements.
    [Show full text]
  • Immediate Hypersensitivity Reactions Caused by Drug Excipients: a Literature Review Caballero ML, Quirce S
    REVIEWS Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review Caballero ML, Quirce S Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain J Investig Allergol Clin Immunol 2020; Vol. 30(2): 86-100 doi: 10.18176/jiaci.0476 Abstract The European Medicines Agency defines excipients as the constituents of a pharmaceutical form apart from the active substance. Immediate hypersensitivity reactions (IHRs) caused by excipients contained in the formulation of medications have been described. However, there are no data on the prevalence of IHRs due to drug excipients. Clinical manifestations of allergy to excipients can range from skin disorders to life-threatening systemic reactions. The aim of this study was to review the literature on allergy to pharmaceutical excipients and to record the IHRs described with various types of medications, specifically reactions due to the excipients contained in their formulations. The cases reported were sorted alphabetically by type of medication and excipient in order to obtain a list of the excipients most frequently involved for each type of medication. Key words: Allergy. Drug immediate hypersensitivity reaction. Excipient. Pharmaceutical excipients. Resumen La Agencia Europea de Medicamentos define los excipientes como los componentes de una forma farmacéutica diferenciados del principio activo. Se han descrito reacciones de hipersensibilidad inmediata causadas por los excipientes contenidos en la formulación de medicamentos. Sin embargo, no hay datos sobre la prevalencia de dichas reacciones. Las manifestaciones clínicas de la alergia a los excipientes pueden ir desde trastornos de la piel hasta reacciones sistémicas que ponen en peligro la vida. El objetivo de este estudio fue realizar una revisión de la literatura sobre la alergia a los excipientes farmacéuticos y recopilar las reacciones inmediatas descritas con diferentes tipos de medicamento, debido solo a excipientes contenidos en sus formulaciones.
    [Show full text]
  • Spanish 2018 Rx4 Traditional Drug List
    Cambios Anuales de Rx4 Traditional 2018 Fecha de entrada en vigor: 01/01/2018 Para visualizarlo en español, haga clic aquí. To view your full Drug List, click here. ¡Bienvenido a Humana! Los cambios al formulario adjunto, o Lista de medicamentos, entran en vigor el 1 de enero de 2018. Visite Humana.com e inicie sesión en MyHumana –su cuenta en línea segura y personal– a partir de la fecha de su renovación para ver los beneficios de medicamentos recetados específicos, incluidos los copagos o el costo compartido, las limitaciones y las exclusiones. También puede consultar su Certificado de cobertura/seguro o su Descripción resumida del plan/Póliza de seguro. Si tiene preguntas: • Posibles afiliados: llamar a Atención al Cliente al número que aparece en los materiales de inscripción • Afiliados actuales: llamar al número indicado al reverso de su tarjeta de identificación de Humana Cómo leer los cambios a su Lista de medicamentos anual Algunos medicamentos cubiertos pueden tener requisitos adicionales o límites en la cobertura. Hable con su médico o proveedor de atención médica si su medicamento tiene un requisito adicional. Estos requisitos y límites pueden incluir: Estatus de la cobertura (CVG, por sus siglas en inglés): Ciertos medicamentos que anteriormente no estaban cubiertos en virtud de los beneficios de su plan se agregarán a su Lista de medicamentos para 2018, mientras que otros medicamentos que quizás estaban cubiertos en el pasado, se eliminarán. Tenga en cuenta que si usted surte o repite la receta de cualquier medicamento no cubierto en virtud de los beneficios de su plan, quizás deba pagar el costo total de su medicamento recetado.
    [Show full text]
  • Evaluation of Chronic Autonomic Symptoms in Gulf War Veterans with Unexplained Fatigue
    Evaluation of Chronic Autonomic Symptoms in Gulf War Veterans with Unexplained Fatigue • Principal Investigator: Dr. Mian Li, WRIISC-DC and Neurology Service at VAMC-DC; Associate Clinical Professor of Neurology • Co-Investigators: Drs Han Kang, Pamela Karasik, Clara Mahan, Friedhelm Sandbrink, Ping Zhai • Post-doctoral fellow: Changqing Xu • Study Coordinator (Volunteer Status): Wenguo Yao • Funded by VA Merit Review Clinical Science R & D • Research approved by local IRB/R & D and conducted in VAMC- DC with compliance of stipulated human research regulations and VA policies regarding report or dissemination of research and non- research information. 1 Rationale • GW veterans (7.7%) reported dizziness/imbalance. blurred vision, excessive fatigue, or tremor (Kang HK, et al. Illnesses among United States veterans of the Gulf War: a population- based survey of 30,000 veterans. J Occup Environ Med 2000; 42(5): 491-501 • Reported neurological symptoms are similar or identical to those from patients with diseases of autonomic nervous system • Ill group (deployed) with post-exertion fatigue • Control (deployed) without fatigue • Objective of this study • Autonomic parameters useful in treatment 2 Peripheral Autonomic Nervous System • Afferent Pathways • Efferent Components parasympathetic and sympathetic • Neurotoxin may preferentially affect small nerve fiber • Small fiber neuropathy vs Autonomic neuropathy • Long delay in diagnosing autonomic system disorder: a) unclear nature course of acquired autonomic disorders b) lack of appropriate
    [Show full text]
  • Saint Pulcheria
    Saint Pulcheria Virgin, Empress of the Eastern Roman Empire In 399 AD, in the city of Constantinople, Aelia to have bishops reinstated who had been unjustly Pulcheria was born to the Easter Roman Emperor Flavius dismissed. Arcadius, and his wife Aelia Eudoxia. Arcadius was a In 421 AD, when Bishop Atticus reported the week and easily controlled emperor, reigning during a persecution of Christians by the Sasanian King Bahram V time when the empire was being invaded by various after the destruction of a Zoroastrian temple, Pulcheria Gothic armies comprised primarily of Arian-Christians influenced her brother to send troops to defend the who believed Jesus Christ, the Son, was a creation of the Christians in the Sassanid Empire. After a successful Father, rather than of one substance with the Father. campaign which Theodosius attributed to his sisters piety Pulcheria had an older sister who had passed away young. and virginity, Christians were allowed to return to In 400 AD, her sister Arcadia would be born, followed by Sassanid. During this time, Theodosius married a pagan Theodosius II and Mariana in 401 AD. In 402 AD, who took the name Aelia Eudocia, and converted to Arcadius went on to declare his one year old son Christianity. Theodosius II to be his co-Emperor. In 431 AD, the Ecumenical Council of Ephesus Despite the fact that Pulcheria’s family were was called to address an issue with the Nestorius of Nicene-Christians and accepted the reality of the Trinity, Constantinople, who denied Mary as the Theotokos, the her mother Eudoxia was in constant conflict with the “God-bearer.” Pulcheria supported Cyril of Alexandria, Patriarch of Constantinople, Saint John Chrysostom.
    [Show full text]